AI Engines For more Details: Perplexity Kagi Labs You
Uterine Contraction: Methylergometrine maleate stimulates uterine contractions by acting directly on uterine smooth muscle. This contraction helps to reduce bleeding by compressing blood vessels and promoting the expulsion of clots or tissue.
Treatment of Postpartum Hemorrhage: Methylergometrine maleate is commonly administered after childbirth to help prevent or manage postpartum hemorrhage, a potentially life-threatening complication characterized by excessive bleeding following delivery.
Management of Abortion/Miscarriage: It is also used to control bleeding after abortion or miscarriage by promoting uterine contraction and reducing blood loss.
Induction of Labor: In some cases, methylergometrine maleate may be used to induce labor or strengthen contractions during childbirth, particularly if there is concern about excessive bleeding.
Side Effects: While methylergometrine maleate is generally well-tolerated, it can cause side effects in some individuals, including:
Contraindications: Methylergometrine maleate should not be used in certain situations, including:
Precautions: It should be used with caution in individuals with a history of cardiovascular disease, hepatic impairment, or renal dysfunction. Close monitoring is necessary in such cases to prevent complications.
Dosage and Administration: Methylergometrine maleate is typically administered as an injection, either intramuscularly or intravenously. The dosage and frequency of administration depend on the specific indication and the patient's response to treatment.
Postpartum Care: After administration of methylergometrine maleate, healthcare providers should closely monitor the patient for signs of adverse effects and provide appropriate postpartum care, including monitoring vital signs and assessing uterine tone and bleeding.
Breastfeeding: Methylergometrine may pass into breast milk, so breastfeeding mothers should be cautious when using this medication. It is generally recommended to avoid breastfeeding for at least 12 to 24 hours after receiving methylergometrine to minimize exposure to the infant.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 3.1 | 0.3 | 9.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2 | 2.1 | -0.05 |
| Allergies | 4.1 | 3.2 | 0.28 |
| Allergy to milk products | 1.7 | 0.6 | 1.83 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3.6 | 4.9 | -0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.9 | 1.56 |
| Ankylosing spondylitis | 2.8 | 1.1 | 1.55 |
| Anorexia Nervosa | 1.2 | 2.3 | -0.92 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 4.4 | 3.3 | 0.33 |
| Atherosclerosis | 1.2 | 1.7 | -0.42 |
| Atrial fibrillation | 2.5 | 0.6 | 3.17 |
| Autism | 6.5 | 5.8 | 0.12 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 1.1 | 1.4 | -0.27 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 2.3 | -2.83 |
| Carcinoma | 2.7 | 2.2 | 0.23 |
| Celiac Disease | 1.3 | 3.3 | -1.54 |
| Cerebral Palsy | 1.7 | 1.3 | 0.31 |
| Chronic Fatigue Syndrome | 3.6 | 3.4 | 0.06 |
| Chronic Kidney Disease | 3.5 | 2.1 | 0.67 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 1.4 | -0.75 |
| Chronic Urticaria (Hives) | 0.8 | 0.6 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
| Cognitive Function | 2.6 | 1.6 | 0.63 |
| Colorectal Cancer | 3.9 | 1.6 | 1.44 |
| Constipation | 0.9 | 0.7 | 0.29 |
| Coronary artery disease | 1.1 | 1.5 | -0.36 |
| COVID-19 | 6.8 | 9 | -0.32 |
| Crohn's Disease | 4.4 | 4.2 | 0.05 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 0.4 | 1.4 | -2.5 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 7 | 6.9 | 0.01 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1 | 1.6 | -0.6 |
| Endometriosis | 1.6 | 1.7 | -0.06 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.9 | 1.7 | 0.12 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 2.6 | 0.8 | 2.25 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 3 | -0.03 |
| gallstone disease (gsd) | 1.7 | 1.2 | 0.42 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1.2 | -3 |
| Generalized anxiety disorder | 1.6 | 2 | -0.25 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.5 | 0.6 | 3.17 |
| Graves' disease | 1.5 | 3 | -1 |
| Gulf War Syndrome | 0.6 | 1.3 | -1.17 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.4 | 1.8 | 0.89 |
| Heart Failure | 1.8 | 1.6 | 0.13 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.9 | 0.6 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.5 | 1.7 | -0.13 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4 | 4.4 | -0.1 |
| Hypothyroidism | 0.4 | 0.7 | -0.75 |
| Hypoxia | 1.9 | 0.3 | 5.33 |
| IgA nephropathy (IgAN) | 1.2 | 2.7 | -1.25 |
| Inflammatory Bowel Disease | 5.2 | 6.9 | -0.33 |
| Insomnia | 1.8 | 3.1 | -0.72 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 6.5 | 4 | 0.63 |
| ischemic stroke | 2.1 | 0.8 | 1.63 |
| Liver Cirrhosis | 5.4 | 4.3 | 0.26 |
| Long COVID | 4.3 | 6.4 | -0.49 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.7 | 1.6 | -1.29 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.5 | 1.5 | -2 |
| ME/CFS without IBS | 1.4 | 1.5 | -0.07 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.7 | 0.9 | 0.89 |
| Metabolic Syndrome | 5.3 | 6.3 | -0.19 |
| Mood Disorders | 7.8 | 5.2 | 0.5 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 5 | 2.8 | 0.79 |
| Multiple system atrophy (MSA) | 1.6 | 0.7 | 1.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.9 | -8.67 |
| Neuropathy (all types) | 1.1 | 1 | 0.1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 4.8 | -0.17 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 8.8 | 7 | 0.26 |
| obsessive-compulsive disorder | 2.9 | 3.3 | -0.14 |
| Osteoarthritis | 1.8 | 1.5 | 0.2 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.9 | 4.3 | 0.6 |
| Polycystic ovary syndrome | 3.5 | 3.3 | 0.06 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.7 | 1.5 | 0.13 |
| Psoriasis | 2.7 | 1.4 | 0.93 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 2.9 | 1.03 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 5.5 | 2.7 | 1.04 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 1.6 | 1.9 | -0.19 |
| Sleep Apnea | 1.6 | 1.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.5 | 1.2 |
| Stress / posttraumatic stress disorder | 2.3 | 2.4 | -0.04 |
| Systemic Lupus Erythematosus | 2 | 2.1 | -0.05 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 2.4 | 3.7 | -0.54 |
| Type 2 Diabetes | 5.1 | 4.8 | 0.06 |
| Ulcerative colitis | 3.2 | 4 | -0.25 |
| Unhealthy Ageing | 2.8 | 1.5 | 0.87 |
| Vitiligo | 1.5 | 0.9 | 0.67 |
